Corrigendum to "Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer" [Clin Breast Cancer 2020; 20:262-73.e7].

The authors regret to inform that we recently noticed a mistake in some of the results of our manuscript published earlier. These mistakes are present in the RESULTS section, sub-section “RFS in the FinHer Dataset,” in the analyses that correspond to Figures 4, 5A-B, and 6A-B, which refer to analyses performed in the dataset from the FinHer trial.Figure 5Kaplan-Meier curves of relapse-free survival according to ADRB2 expression in patients who received chemotherapy and trastuzumab (n = 102, A); and in those who received chemotherapy alone (n = 100, B) in the FinHer study.Abbreviations: ADRB2 = beta-2 adrenergic receptor; CI = confidence interval; HR = hazard ratio.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 6Kaplan-Meier curves of relapse-free survival according to ADRB2 expression in hormone-receptor positive (n = 97, A) and hormone-receptor negative patients (n = 105, B) in the FinHer study.Abbreviations: ADRB2 = beta-2 adrenergic receptor; CI = confidence interval; HR = hazard ratio.View Large Image Figure ViewerDownload Hi-res image Download (PPT) In statistical analyses, typically “1” is used to encode an event (death or recurrence), and “0” to encode “no event.” In this dataset, however, the annotation was reversed, with events being encoded as “0,” instead. Our team did not realize this specificity when performing the original analyses, consequently the RFS analyses and the Kaplan-Meier curves that correspond to the FinHer dataset were impacted by an inversion in the categorization of events: RFS events were counted as “no events” whereas “no events” were counted as RFS events, erroneously. After identifying the issue, our team reperformed the same analyses with the correct event categorization for this respective dataset, which generated new hazard ratios and Kaplan-Meier curves for RFS, accordingly. Importantly, the overall interpretation of the results from this section, as well as the discussion section of the manuscript were not substantially affected by this mistake, because none of the updated RFS analyses showed statistically significant results or results that were significantly different from the wrong ones reported in the original manuscript. Our team performed a thorough verification of all other statistical analyses performed as part of this manuscript, and we herein confirm there were no mistakes in the other results of this publication, the mistake affected exclusively the analyses performed in the FinHer dataset. Based on our commitment to provide accurate information for Clinical Breast Cancer readers, we herein provide the updated statistical analyses performed with the correct event categorization for the FinHer dataset. The authors would like to apologize for any inconvenience caused. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast CancerClinical Breast CancerVol. 20Issue 3PreviewMicro-Abstract ADRB2 mediates trastuzumab resistance in preclinical models of HER2+ breast cancer. We evaluated ADRB2 gene expression as a prognostic and predictive biomarker in HER2+ early breast cancer patients. Opposing our initial hypothesis, a high ADRB2 expression may exert antiproliferative, antiangiogenic, and immunogenic effects, and thus be associated with a favorable prognosis in patients with HER2+ early breast cancer. Full-Text PDF